Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arctic Bioscience AS ( (DE:9TD) ) has provided an update.
Arctic Bioscience has reported that new research on herring roe oil and its phospholipid esters has been accepted for publication in the Journal of Lipid Research, underscoring the scientific basis of its marine-derived technologies. The peer-reviewed study shows that these compounds increase production of specialized pro-resolving mediators in human immune and skin cell models relevant to psoriasis, indicating a mechanism by which the company’s investigational drug HRO350 may help resolve inflammation.
Company executives say the data provide important mechanistic insight into how HRO350 could act in psoriasis and other immune-mediated diseases, reinforcing the rationale for its clinical development as a potential oral option for mild-to-moderate psoriasis patients seeking safer, better-tolerated therapies. The research, conducted with UK and Norwegian partners and partially grant-funded, strengthens Arctic Bioscience’s positioning in inflammation-targeted dermatology and supports continued investment in its R&D pipeline.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech company focused on developing and commercializing pharmaceutical and nutraceutical products derived from bioactive marine compounds, particularly herring roe oil. Its lead drug candidate, HRO350, is an oral treatment in development for patients with mild-to-moderate psoriasis, while its nutraceutical offerings are sold globally as bulk ingredients and finished products under the ROMEGA brand.
Average Trading Volume: 16,099
Current Market Cap: NOK91.11M
Find detailed analytics on 9TD stock on TipRanks’ Stock Analysis page.